PMID- 20519099
OWN - NLM
STAT- MEDLINE
DCOM- 20100907
LR  - 20191111
IS  - 1488-2353 (Electronic)
IS  - 0147-958X (Linking)
VI  - 33
IP  - 3
DP  - 2010 Jun 1
TI  - Protective effects of combined Mycobacterium bovis BCG and interleukin-12 
      vaccination on airway inflammation in a murine model of allergic asthma.
PG  - E196-202
AB  - PURPOSE: Allergic asthma is characterized by chronic airway inflammation and 
      airway hyperresponsiveness driven by allergen-specific T helper (Th)2 cells. 
      Mycobacterium bovis bacillus Calmette-Guerin (BCG) vaccination has been 
      documented to suppress Th2 responses and allergic airway inflammation in animal 
      models. Since interleukin (IL)-12 is capable of inhibiting Th2 responses, we 
      sought to investigate whether IL-12 could function as an adjuvant to increase the 
      efficacy of BCG vaccination against allergic asthma. METHODS: BALB/c neonatal 
      mice (24 mice, 48-72 h old) were randomly divided into 3 subgroups (n = 8 for 
      each group) to be immunized with PBS (control) or BCG with or without DNA 
      plasmid-expressing IL-12. All of the mice were then sensitized and provoked with 
      ovalbumin (OVA) to establish a model of allergic asthma. RESULTS: Mice vaccinated 
      with BCG alone showed a significant reduction in airway inflammation, percentage 
      of eosinophils in bronchoalveolar lavage (BAL) fluid, and serum OVA-specific 
      immunoglobulin E (IgE) levels in comparison with control animals. The suppressive 
      effects of BCG were substantially augmented by the combination with IL-12. 
      Furthermore, a decreased IL-4 and increased interferon-gamma (IFN-gamma) 
      production in BAL fluid were observed in animals inoculated with BCG alone or 
      with IL-12 relative to control animals. CONCLUSION: Our data indicate that the 
      combined vaccination with BCG and IL-12 yields a favorable outcome in prevention 
      of experimental allergic airway inflammation, which is likely mediated through 
      triggering a shift from a Th2 response to a Th1 response.
FAU - Ke, Xia
AU  - Ke X
AD  - Department of Otolaryngology, First Affiliated Hospital, Chongqing Medical 
      University, Chongqing 400016, China.
FAU - Huang, Jiangju
AU  - Huang J
FAU - Chen, Quan
AU  - Chen Q
FAU - Hong, Suling
AU  - Hong S
FAU - Zhu, Daoyin
AU  - Zhu D
LA  - eng
PT  - Journal Article
DEP - 20100601
PL  - Canada
TA  - Clin Invest Med
JT  - Clinical and investigative medicine. Medecine clinique et experimentale
JID - 7804071
RN  - 187348-17-0 (Interleukin-12)
RN  - 207137-56-2 (Interleukin-4)
RN  - 82115-62-6 (Interferon-gamma)
RN  - 9006-59-1 (Ovalbumin)
SB  - IM
MH  - Animals
MH  - Animals, Newborn
MH  - Asthma/chemically induced/*immunology/metabolism
MH  - Bronchoalveolar Lavage Fluid/chemistry
MH  - Disease Models, Animal
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Interferon-gamma/metabolism
MH  - Interleukin-12/immunology/*pharmacology
MH  - Interleukin-4/metabolism
MH  - Male
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mycobacterium bovis/*immunology
MH  - Ovalbumin/toxicity
MH  - Respiratory System/drug effects
EDAT- 2010/06/04 06:00
MHDA- 2010/09/08 06:00
CRDT- 2010/06/04 06:00
PHST- 2010/06/01 00:00 [received]
PHST- 2010/06/04 06:00 [entrez]
PHST- 2010/06/04 06:00 [pubmed]
PHST- 2010/09/08 06:00 [medline]
AID - 10.25011/cim.v33i3.13726 [doi]
PST - epublish
SO  - Clin Invest Med. 2010 Jun 1;33(3):E196-202. doi: 10.25011/cim.v33i3.13726.